ClinicalTrials.gg
RecruitingNCT03610802Updated Nov 12, 2026

Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies

An observational study in Primary Immunodeficiency, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Recruiting at 3 sites in 3 countries. Open to participants aged 1 Day to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Observational

How we know

From the registry’s dates

  • Started Jul 2019; still recruiting 7 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,000
Ages
1 Day to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Primary Immunodeficiency Diseases by National Institute of Allergy and Infectious Diseases (NIAID) — 11 open to participants now, 11 under way, none of them phase 3. Primary Immunodeficiency Diseases · National Institute of Allergy and Infectious Diseases (NIAID).

Planned enrollment
4th of 11
3,000 · median 1,190
Started
2019
the only one that year
Observational
11 of 16
10 open now
Registered
13th of 16
by date

Among the 16 studies in Primary Immunodeficiency Diseases by National Institute of Allergy and Infectious Diseases (NIAID), this one is the 4th largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2019, is one of 11 observational ones, and was the 13th registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

11 of the 16 studies in Primary Immunodeficiency Diseases by National Institute of Allergy and Infectious Diseases (NIAID) are open now, in 4 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 1 Day to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Primary Immunodeficiency Diseases by National Institute of Allergy and Infectious Diseases (NIAID), or all of them as a file.
02

Study summary

Background:

The immune system helps the body fight infections. Primary immunodeficiency disorders (PIDs) are diseases that make it easier for people to get sick. Many PIDs are inherited. This means parents can pass them on to their children. Knowing what causes a person s PID is important to decide what treatment to give them.

Objective:

To test samples from people with a PID or people related to someone with a PID to find out what causes PIDs.

Eligibility:

People ages 99 or younger who have a PID or have a relative with a PID

Design:

Participants will be screened with a medical history over the phone. They may need to give permission for researchers talk to their doctors about their health. Their relatives may be contacted to see if they want to join the study.

Participants will give samples. These could be:

Blood: Participants blood will be taken from a vein in an arm, or with a prick on the finger or heel for children.

Saliva, urine, or stool: Participants will provide each sample in a special cup.

Nose or cheek swab: Participants will rub the skin inside their nose or cheek using a cotton swab.

Cord blood: If participants have a baby during the study, blood will be collected from the baby s umbilical cord after it is born.

Samples from medical procedures: If, during the study, the participants have a medical procedure that collects samples, the samples may be used for the study.

Read the detailed description

Study Design:

This is a prospective sample collection protocol to receive send-in biological samples. Participants will not be seen at the NIH for study visits. Under this protocol, genetic and molecular tests will be performed on samples to improve understanding of PIDs. Findings relevant to participants health and medical care will be returned to them and their referring healthcare providers.

Primary Objective:

To achieve genetic and immunologic characterization of known or suspected disorders of the immune system.

Primary Endpoints:

  1. Identification of genetic variants that are associated with PID.
  2. Identification of patients with abnormalities of the immune system that may be enrolled in other NIH protocols.

This is a sample collection protocol to receive send-in samples (blood, tissue, and other bodily fluids) from patients with known or suspected primary immunodeficiency disorder (PID) and their relatives. Under this protocol, genetic and molecular tests will be performed on samples to improve understanding of PIDs and immune system abnormalities. Findings relevant to participants health and medical care will be returned to them and their referring healthcare providers.

03

Conditions studied

  • Primary Immunodeficiency

Keywords

  • Immunophenotyping
  • Functional Assays
  • Repository
  • HLA-Typing
  • Next Generation Sequencing
  • Natural History
04

Who can participate

Ages eligible
1 Day to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with Primary Immune Deficiency or Dysregulatory Disorder and their biological relatives will be referred by healthcare providers worldwide.@@@@@@

Eligibility criteria

  • INCLUSION CRITERIA:

Participants enrolled onto this protocol must meet all of the following criteria:

  1. Age 0-99 years.
  2. Meets 1 of the following criteria:

    1. Patient with a clinical diagnosis of a form of PID (either known or suspected). PID may be defined by laboratory and/or clinical findings on 2 or more occasions that are consistent with a defect in innate or adaptive immunity. Specific PIDs are defined by the guidelines of the International Union of Immunological Societies.
    2. Biological relative of an individual meeting criterion 2a, with no clinical evidence of having a PID. Relatives may be mother, father, siblings, children, grandparents, aunts, uncles, or first cousins to an individual with a known or suspected PID.
  3. Able to provide .
  4. Willing to allow genetic testing and allow biospecimens to be modified into induced pluripotent stem (iPS) cells.
  5. Willing to allow storage of samples and data for future research.

EXCLUSION CRITERIA:

Individuals meeting any of the following criteria will be excluded from study participation:

  1. History of secondary causes of immunodeficiency (eg, infection, immunodeficiency from chronic use of or chemotherapeutic agents), at the discretion of the investigator.
  2. Any condition that, in the opinion of the investigator, contraindicates participation in this study.

INCLUSION/EXCLUSION OF SPECIAL POPULATIONS:

Children: Children are eligible to participate in this study because PIDs may present in early childhood and results of some research tests may inform participants future medical care. Additionally, the study poses no more than minimal risk.

Pregnant women and neonates: Pregnant women can participate in this study. Research testing on samples from pregnant women may help us learn about changes in the immune systems of immunodeficient patients during pregnancy, which is important knowledge that could not be obtained from nonpregnant individuals. Research testing of pregnant women with known or suspected PIDs could provide insight into the fetus s health risks, which may help guide clinical management during and after pregnancy. We may request cord blood samples at delivery to process right away or freeze. Cord blood is a unique source of stromal cells that may be characterized or modified for research purposes. Additionally, this study poses no more than minimal risk, including to participants who are pregnant and their fetuses. Similarly, neonates (including nonviable neonates or those of uncertain viability) may be enrolled in this study as it does not involve more than minimal risk and blood volumes will be limited based on the clinical status of each participant. Each individual providing consent will be fully informed regarding the reasonably foreseeable impact of the research on the neonate, and individuals engaged in the research will have no part in determining the viability of a neonate. Further, neonates of uncertain viability are eligible because all the following criteria are met:

  • Many PIDs are rare and present early in life, and it is possible that the manifestations of a known or suspected PID may impact the viability of the neonate. Research testing of neonates with known or suspected PIDs could provide insight into current and future health risks, which may provide guidance for medical management and thus benefit the neonate and possibly enhance the probability of survival.
  • The only risks of study participation are the risks of blood draw. When possible, blood for this study will be collected at the time of clinically indicated blood draws so that there is no additional needlestick, and blood volumes will be limited based on the clinical status of each participant. Collection of blood is the only possible method to conduct the research testing under this protocol that may directly benefit the neonate by revealing insights about health risks and medical management. Thus, the risk is the least possible for achieving that objective.
  • The legally effective informed consent of either parent of the neonate or, if neither parent is able to consent because of unavailability, incompetence, or temporary incapacity, the legally effective informed consent of either parent's legally authorized representative is obtained, except that the consent of the father or his legally authorized representative need not be obtained if the pregnancy resulted from rape or incest.

Nonviable neonates are also eligible because all the following criteria are met:

  • Vital functions of the neonate will not be artificially maintained.
  • The research will not terminate the heartbeat or respiration of the neonate.
  • Blood will only be collected from nonviable neonates at the time of clinically indicated blood draws so that there is no additional needlestick, and blood volumes will be limited based on the clinical status of each participant. Therefore, there will be no added risk to the neonate resulting from the research.
  • As described above, many known or suspected PIDs are rare and can present early during life, and it is possible that their manifestations may impact the viability of the neonate. This protocol aims to achieve characterization of such disorders, and this aim could not be achieved for certain disorders if nonviable neonates are excluded. Thus, the purpose of the research is the development of important biomedical knowledge that cannot be obtained by other means.
  • The legally effective informed consent of both parents of the neonate will be obtained.

Decisionally impaired adults: Adults who are unable to consent are excluded from study participation. Enrolled participants who temporarily lose the ability to consent during study participation may continue in the study in accordance with NIH Human Research Protections Program (HRPP) Policy 403 Research with Subjects Lacking Capacity to Consent; the study poses no more than minimal risk and may hold a prospect of direct benefit as results of some research tests may inform participants future medical care. However, enrolled participants who permanently lose the ability to consent during study participation will be withdrawn.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,000 participants (estimated)

Groups and cohorts

  • Biological relatives

    Biological relative (mother, father, siblings, children, grandparents, aunts, uncles, or first cousins) of patient, with no clinical evidence of having a PID.

  • Patients

    Patients with PID, which may be defined by laboratory and/or clinical findings on 2 or more occasions that are consistent with a defect in innate or adaptive immunity.

06

What researchers measure

Primary outcomes

  1. Identification of patients with abnormalities of the immune system that may be enrolled in other NIH protocols

    Identification of patients with abnormalities of the immune system that may be enrolled in other NIH protocols. To achieve genetic and immunologic characterization of known or suspected disorders of the immune system.

    Time frame: Duration of participant enrollment

  2. Identification of genetic variants that are associated with PID.

    To achieve genetic and immunologic characterization of known or suspected disorders of the immune system.

    Time frame: Duration of participant enrollment

Secondary outcomes

  1. Identification of molecular and functional abnormalities associated with known or novel forms of PID (repository study).

    Identification of molecular and functional abnormalities associated with known or novel forms of PID (repository study).

    Time frame: Duration of participant enrollment

07

Study locations

3 of 3 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) · Contactprpl@cc.nih.gov · 800-411-1222
  • Pavia Hospital (PH)
    Pavia, 27100, Italy
    Recruiting
  • Marmara University Hospital, Istanbul Jeffrey Modell Diagnostic and Research Cen
    Istanbul, Turkey (Türkiye)
    Recruiting
08

References and documents

Publications

  • Bousfiha AA, Jeddane L, Ailal F, Al Herz W, Conley ME, Cunningham-Rundles C, Etzioni A, Fischer A, Franco JL, Geha RS, Hammarstrom L, Nonoyama S, Ochs HD, Roifman CM, Seger R, Tang ML, Puck JM, Chapel H, Notarangelo LD, Casanova JL. A phenotypic approach for IUIS PID classification and diagnosis: guidelines for clinicians at the bedside. J Clin Immunol. 2013 Aug;33(6):1078-87. doi: 10.1007/s10875-013-9901-6. Epub 2013 May 9. PubMed 23657403 ↗
  • Picard C, Bobby Gaspar H, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Crow YJ, Cunningham-Rundles C, Etzioni A, Franco JL, Holland SM, Klein C, Morio T, Ochs HD, Oksenhendler E, Puck J, Tang MLK, Tangye SG, Torgerson TR, Sullivan KE. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. J Clin Immunol. 2018 Jan;38(1):96-128. doi: 10.1007/s10875-017-0464-9. Epub 2017 Dec 11. PubMed 29226302 ↗
  • Milner JD, Holland SM. The cup runneth over: lessons from the ever-expanding pool of primary immunodeficiency diseases. Nat Rev Immunol. 2013 Sep;13(9):635-48. doi: 10.1038/nri3493. Epub 2013 Jul 26. PubMed 23887241 ↗

Individual participant data

Plan to share: No — The primary focus of this study is to identify genetic variants associated with PID to achieve genetic and immunologic characterization of known or suspected disorders of the immune system

09

Timeline

5 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2019 (actual). Primary completion is estimated for Mar 2038, 224 months after the start.

Of 50 observational studies under Primary Immunodeficiency Diseases, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 30. This study's planned 224 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2018
First posted
Aug 1, 2018
StartActual
Jul 22, 2019
Primary completionEst.
Mar 31, 2038
CompletionEst.
Mar 31, 2038
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: description and verification date
5 updates, last Nov 12, 2026
Show all 5 updates
  1. Nov 12, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 26, 2026
    Minor edits only
    + 1 other change: description
  3. Oct 16, 2026
    Minor edits only
    + 1 other change: description
  4. Oct 8, 2026
    Minor edits only
    + 1 other change: description
  5. Oct 2, 2026
    Minor edits only
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03610802
Responsible party
Sponsor
First posted
Aug 1, 2018
Start date
Jul 22, 2019
Primary completion
Mar 31, 2038 (estimated)
Completion
Mar 31, 2038 (estimated)
Last update
Nov 12, 2026

Study contacts

Pooi M Truong
Contact
pooi.truong@nih.gov
(240) 669-2165
Ottavia M Delmonte, M.D.
Contact
ottavia.delmonte@nih.gov
(240) 669-5473
Ottavia M Delmonte, M.D.
principal investigator · National Institute of Allergy and Infectious Diseases (NIAID)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion